| Source | Population | N | Bevacizumab dose/schedule | Radiographic response definition and rates | Hearing response definition and rates | Key adverse events and rates | Notes |
|---|---|---:|---|---|---|---|---|
| Chiranth et al., 2023, *Neuro-Oncology Advances*, DOI: https://doi.org/10.1093/noajnl/vdad099 | NF2-related schwannomatosis with vestibular schwannoma; pooled systematic review of targeted therapy studies | 200 across 10 bevacizumab studies (16 total studies tested 6 drugs) | Review-level summary; notes that lower-dose bevacizumab may retain efficacy with less toxicity | REiNS volumetric criteria: radiographic response (RR) = >20% tumor-volume decrease; progression = >20% increase. Pooled bevacizumab RR 38% (95% CI 31–45%); bevacizumab had highest efficacy among targeted agents reviewed | Pooled hearing response (HR) 45% (95% CI 36–54%) | Common toxicities: hypertension and menorrhagia | Comparator agents in review: lapatinib RR 6%, HR 31%; VEGFR vaccine RR 29%, HR 40%. Authors conclude bevacizumab showed the highest efficacy, but further trials of other agents/combination therapy are needed (pqac-00000003) |
| Screnci et al., 2024, *Journal of Clinical Medicine*, DOI: https://doi.org/10.3390/jcm13237488 | Neurofibromatosis type 2 / NF2-related vestibular schwannoma; systematic review | 176 across 9 studies | Not consistently reported in pooled excerpt | Partial tumor volume reduction defined as ≥20%: 40%; disease stabilization 50%; progression 10% | Hearing improvement 36%; hearing stabilization 46%; hearing deterioration 18% | Severe adverse effects in 13% (including hypertension and thromboembolic events); 18% reported no side effects | Tumor regrowth observed in some patients after treatment discontinuation, supporting need for long-term monitoring (pqac-00000007) |
| Douwes et al., 2024, *Cancers*, DOI: https://doi.org/10.3390/cancers16081479 | Single-center NF2-related schwannomatosis cohort treated for target vestibular schwannoma | 17 patients; radiology evaluable in 16; hearing evaluable in 15 target ears; post-treatment symptom surveillance in 11; post-treatment radiology in 12 | Median 7.5 mg/kg IV every 3 weeks (range 5.6–7.5; interval range 3.0–4.4 weeks); planned regimen 7.5 mg/kg q3wk for at least 6 months; median duration 7.1 months (range 2.1–23.9) | Definition: improved = ≥20% decrease in extrameatal volume; stable = between −20% and +20%; worsened = ≥20% increase. On treatment: regression 31% (5/16), stable 69% (11/16), no ≥20% progression reported. Median extrameatal volume 1.24 cm^3 to 1.15 cm^3. Pre-treatment growth 43% overall (15% annually) vs −12% overall (−13% annually) during treatment. Post-treatment surveillance: 9% regression, 36% stable, 55% progression | Definition: improved = ≥10% WRS increase; worsened = ≥10% WRS decrease; if WRS remained 100%, ≥10 dB PTA change considered significant. On treatment: 40% improved, 53% stable, 7% worsened in target ears (6/15, 8/15, 1/15); reported as hearing preservation 93%. Median WRS 74% to 82%; median PTA 57 dB to 61 dB. After discontinuation (n=11), 82% stable and 18% hearing loss | 94% had ≥1 adverse event; 50 total AEs: grade 1 62%, grade 2 34%, grade 3 4%, no grade 4/5. Hypertension 82% (grade 3 in 12%; 36% of hypertensive patients required antihypertensives), fatigue 29%, proteinuria 6%. Treatment discontinuation due to AEs in 29% | Indications: progressive hearing loss 59%, other NF2 symptoms 35%, tumor size 6%. Symptoms improved in 41%, stable in 47%, worsened in 12% during treatment; summarized as clinical symptom improvement/preservation in 88%. Reasons for stopping included radiologic stability/regression and/or hearing benefit, AEs (29%), response failure (6%), patient preference (6%). After stopping (median surveillance 29.2 months), 27% remained stable and 73% worsened symptomatically; no further symptom improvement. Four patients were retreated with mixed results; two maintenance-regimen patients remained stable (pqac-00000009, pqac-00000010, pqac-00000011, pqac-00000012, pqac-00000015) |


*Table: This table compiles the main quantitative bevacizumab outcomes for NF2-related vestibular schwannoma from a 2023 systematic review, a 2024 systematic review, and a 2024 single-center cohort. It is useful for comparing pooled efficacy, toxicity, and post-discontinuation patterns across evidence sources.*